2018


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2018/№S2

Проблемы антикоагулянтной терапии у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий: возможности ривароксабана

Кобалава Ж. Д., Виллевальде С. В., Троицкая Е. А.
ФГАОУ ВО «РУДН», 117198, Москва, ул. Миклухо-Маклая, д. 6

Ключевые слова: хроническая сердечная недостаточность, фибрилляция предсердий, прямые оральные антикоагулянты, ривароксабан

DOI: 10.18087/cardio.2447

Фибрилляция предсердий (ФП) и СН – новые эпидемии ССЗ, частое сочетание которых усугубляет неблагоприятный прогноз пациента во многом за счет повышения риска тромбоэмболических осложнений. В обзоре рассмотрены основные данные об эпидемиологии, механизмах и прогнозе при сочетании СН и ФП, подходах к назначению прямых оральных антикоагулянтов (ПОАК) и возможностях ривароксабана.
  1. Braunwald E. Shattuck lecture – cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337 (19):1360–9. DOI:10.1056/NEJM199711063371906
  2. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7. [Ageev F. T., Danielyan M. O., Mareev V. Y. et al. Patients with chronic heart failure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies of AGE-O-CHF). Russian Heart Failure Journal. 2004;5 (1):4–7.]
  3. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. et al. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН (Часть II). Журнал Сердечная Недостаточность. 2006;7 (3):112–5. [Fomin I. V., Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Badin Yu.,V. et al. Prevalence of chronic heart failure in European part of Russian Federation – Data of AGECHF (Part II). Serdechnaya Nedostatochnost’ 2006;7 (1):112–5.]
  4. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129 (8):837–47. DOI:10.1161/CIRCULATIONAHA.113.005119
  5. Lubitz SA, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. Heart Fail Clin. 2010;6 (2):187–200. DOI:10.1016/j.hfc.2009.11.001
  6. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107 (23):2920–5. DOI:10.1161/01.CIR.0000072767.89944.6E
  7. Savelieva I, John Camm A. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace. 2004;5 Suppl 1: S5–19. DOI:10.1016/j.eupc.2004.07.003
  8. Khan MA, Ahmed F, Neyses L, Mamas MA. Atrial fibrillation in heart failure: The sword of Damocles revisited. World J Cardiol. 2013;5(7):215–27. DOI:10.4330/wjc.v5.i7.215
  9. Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation. Eur J Heart Fail. 2015;17 (6):570–82. DOI:10.1002/ejhf.254
  10. Chiang C-E, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O’Neill J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5 (4):632–9. DOI:10.1161/CIRCEP.112.970749
  11. Odutayo A, Wong CX, Williams R, Hunn B, Emdin CA. Prognostic Importance of Atrial Fibrillation Timing and Pattern in Adults With Congestive Heart Failure: A Systematic Review and Meta-Analysis. J Card Fail. 2017;23 (1):56–62. DOI:10.1016/j.cardfail.2016.08.005
  12. Chatterjee NA, Chae CU, Kim E, Moorthy MV, Conen D, Sandhu RK et al. Modifiable Risk Factors for Incident Heart Failure in Atrial Fibrillation. JACC Heart Fail. 2017;5 (8):552–60. DOI:10.1016/j.jchf.2017.04.004
  13. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J. 2015;36 (46):3250–7. DOI:10.1093/eurheartj/ehv513
  14. Verma A, Kalman JM, Callans DJ. Treatment of Patients With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. Circulation. 2017;135 (16):1547–63. DOI:10.1161/CIRCULATIONAHA.116.026054
  15. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210
  16. Abraham JM, Connolly SJ. Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. Heart Fail Rev. 2014;19 (3):305–13. DOI:10.1007/s10741‑014‑9420‑4
  17. Zannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM et al. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol. 2013;167 (5):1772–82. DOI:10.1016/j.ijcard.2012.12.018
  18. Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5 (8):565–74. DOI:10.1016/j.jchf.2017.05.001
  19. Abdul-Rahim AH, Perez A-C, Fulton RL, Jhund PS, Latini R, Tognoni G et al. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca-Heart Failure (GISSIHF) Trials. Circulation. 2015;131 (17):1486–1494; discussion 1494. DOI:10.1161/CIRCULATIONAHA.114.013760
  20. Терещенко С. Н., Романова Н. В., Жиров И. В., Осмоловская Ю. Ф., Голицын С. П. Российский регистр больных хронической сердечной недостаточностью и фибрилляцией предсердий (РИФ-ХСН): клинико-демографические характеристики выборки на момент включения в регистр. Журнал Сердечная Недостаточность. 2016;17(6):418–26. [Tereshchenko S. N., Romanova N. V., Zhirov I. V., Osmolovskaya Yu. F., Golitsyn S. P. Russian Registry of Patients with Chronic Heart Failure and Atrial Fibrillation (RIF-CHF): Clinical and demographic characteristics of the sample upon inclusion into the Registry. Russian Heart Failure Journal. 2016;17 (6):418–426.] DOI:10.18087/rhfj.2016.6.2276
  21. Терещенко С. Н., Жиров И. В., Романова Н. В., Осмоловская Ю. Ф., Голицын С. П. Первый Российский регистр больных Хронической Сердечной Недостаточностью И Фибрилляцией предсердий (РИФ–ХСН): дизайн исследования. Рациональная фармакотерапия в кардиологии. 2015;11 (6):577–81. [Tereshchenko S. N., Zhirov I. V., Romanova N. V., Osmolovskaya Yu. F., Golitsyn S. P. The first Russian register of patients with chronic heart failure and atrial fibrillation (RIFCHF): study design. Rational Pharmacotherapy in Cardiology. 2015;11(6):577–581.] DOI:10.20996/1819‑6446‑2015‑11‑6‑577‑581
  22. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А., et al. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18(1):3–40. [Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. et al. Clinical guidelines. Chronic heart failure (CHF). Russian Heart Failure Journal. 2017;18(1):3-40.] DOI:10.18087/rhfj.2017.1.2346
  23. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI:10.1093/eurheartj/ehw128
  24. Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail. 2013;15 (9):1053–61. DOI:10.1093/eurjhf/hft111
  25. Lip GYH, Heinzel FR, Gaita F, Juanatey JRG, Le Heuzey JY, Potpara T et al. European Heart Rhythm Association / Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail. 2015;17 (9):848–74. DOI:10.1002/ejhf.338
  26. Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GYH. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials: Characteristics of included RCTs NOACs in patients with concomitant AF and HF. European Journal of Heart Failure. 2015;17 (11):1192–200. DOI:10.1002/ejhf.343
  27. Savarese G, Giugliano RP, Rosano GMC, McMurray J, Magnani G, Filippatos G et al. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail. 2016;4 (11):870–80. DOI:10.1016/j.jchf.2016.07.012
  28. Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the International, Observational, Prospective GARFIELD Registry. Hernandez AV, editor. PLoS ONE. 2013;8 (5):e63479. DOI:10.1371/journal.pone.0063479
  29. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365 (10):883–91. DOI:10.1056/NEJMoa1009638
  30. van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013;6 (4):740–7. DOI:10.1161/CIRCHEARTFAILURE.113.000212
  31. McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new chronic kidney disease-epidemiology collaboration group formula. Circulation: Heart Failure. 2012;5 (3):309–14. DOI:10.1161/CIRCHEARTFAILURE.111.966242
  32. Fordyce CB, Hellkamp AS, Lokhnygina Y, Lindner SM, Piccini JP, Becker RC et al. On-Treatment Outcomes in Patients With Worsen ing Renal Function With Rivaroxaban Compared With Warfarin Clinical Perspective: Insights From ROCKET AF. Circulation. 2016;134(1):37–47. DOI:10.1161/CIRCULATIONAHA.116.021890
  33. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011;32(19):2387–94. DOI:10.1093/eurheartj/ehr342
  34. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365 (11):981–92. DOI:10.1056/NEJMoa1107039
  35. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009;361 (12):1139–51. DOI:10.1056/NEJMoa0905561
  36. IMS Health MIDAS компании Quintiles: IMS MIDAS Q4 2015. MIDAS® [Internet]. [cited 2018].
  37. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GYH, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. DOI:10.1136/bmj.j510
  38. Cleland JG., Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C et al. The Warfarin/Aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal. 2004;148 (1):157–64. DOI:10.1016/j.ahj.2004.03.010
  39. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Wafarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial. Circulation. 2009;119(12):1616–24. DOI:10.1161/CIRCULATIONAHA.108.801753
  40. Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine. 2012;366 (20):1859–69. DOI:10.1056/NEJMoa1202299
  41. Zannad F, Greenberg B, Cleland JGF, Gheorghiade M, van Veldhuisen DJ, Mehra MR et al. Rationale and design of a randomized, doubleblind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and signi: Rationale and design of COMMANDER HF. European Journal of Heart Failure. 2015;17 (7):735–42. DOI:10.1002/ejhf.266
  42. Diaz A, Ciocchini C, Esperatti M, Becerra A, Mainardi S, Farah A. Precipitating factors leading to decompensation of chronic heart failure in the elderly patient in South-American community hospital: Precipitating factors leading to decompensation of chronic heart failure in the elderly patient in South-American community hospital. Journal of Geriatric Cardiology. 2011;8 (1):12–4. DOI: 10.3724/SP.J.1263.2011.00012
  43. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 2016;37 (14):1145–53. DOI:10.1093/eurheartj/ehv466
  44. McMurray JJV, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013;6 (3):451–60. DOI:10.1161/CIRCHEARTFAILURE.112.000143
  45. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiology. 2016;1 (4):451. DOI:10.1001/jamacardio.2016.1170
  46. Böhm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA et al. Changes in renal function in patients with atrial fibrillation. Journal of the American College of Cardiology. 2015;65(23):2481–93. DOI:10.1016/j.jacc.2015.03.577
Кобалава Ж. Д., Виллевальде С. В., Троицкая Е. А. Проблемы антикоагулянтной терапии у пациентов с хронической сердечной недостаточностью и фибрилляцией предсердий: возможности ривароксабана. Кардиология. 2018;58(S2):33–41

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En